Camrelizumab for Advanced Squamous Non-Small Cell Lung Carcinoma: Caicun Zhou, MD, PhD

Recently, the results of a phase 3 trial on camrelizumab were published in the Journal of Thoracic Oncology and presented at the European Lung Cancer Virtual Congress 2021. Camrelizumab was studied in the randomized, double-blind, multicenter trial as a treatment for advanced squamous non-small cell lung carcinoma (NSCLC). Patients with stages IIIB-IV squamous NSCLC were treated with carboplatin plus paclitaxel with camrelizumab or placebo in the first-line setting. Compared with those who recei...
Continue reading

Adjuvant Icotinib Effective for EGFR-Mutated Non-Small Cell Lung Cancer

In patients with stage II–IIIA epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), icotinib significantly improved disease-free survival in the adjuvant setting compared with standard chemotherapy, according to results of a phase 3 trial recently presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer. "Recent studies have shown significant benefits of EGFR tyrosine kinase inhibitors in the adjuvant sett...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.